🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Exploratory Study of Cerebral Perfusion and Metabolic Alterations and Neurocognitive Disorders in Patients With Unruptured Arteriovenous Malformations Before and After Surgical Treatment

RecruitingNAAges 18 Years - anyAllUniversity Hospital, Montpellier
NCT07569887 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of the clinical trial is to describe perfusion and metabolic alterations in different brain regions before and six months after surgical treatment of arteriovenous malformations in adult patients with unruptured arteriovenous malformations.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adults aged 18 and older * Admitted for an unruptured arteriovenous malformation with a decision to proceed with surgery Exclusion Criteria: * Patients who refuse surgical treatment for arteriovenous malformation * Contraindications to 18F-FDG PET (uncontrolled diabete) * Patients' inability to lie still for 40 minutes * Patients with a confirmed diagnosis of neurodegenerative or psychiatric disorders * Pregnant or breastfeeding women (Article L.1121-5 of the French Public Health Code) * Persons deprived of their liberty by judicial or administrative decision (Article L.1121-6 of the French Public Health Code) * Persons who are subject to legal protection measures or who are unable to express their consent (guardianship, curatorship, judicial protection; Article L.1121-8 of the French Public Health Code) * Not affiliated with a social security scheme or beneficiary of such a scheme (Article L.1121-8-1 of the French Public Health Code) * Persons participating in another study that includes an ongoing exclusion period (Article L.1121-12 of the French Public Health Code) * Failure to obtain written informed consent
💊

What it tests

  • 18F-FDG PET imaging
  • Neuropsychological Assessment
📍

Where

1 site
CHU de Montpellier
Montpellier, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy